Publication
Number of items: 8.
Public
Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders : A pharmacovigilance perspective. (2025)
S Chiappini,
A Guirguis,
N Schifano,
J Corkery,
F Semeraro,
A Mosca,
G D'Andrea,
G D Papanti,
D Arillotta,
G Floresta,
G Martinotti
and
F Schifano
![]()
The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine) : A brief review. (2012)
John Corkery,
E. Durkin,
S. Elliott,
Fabrizio Schifano
and
A. Hamid Ghodse
![]()
High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients. (2020)
Norbert Scherbaum,
Friedrich Seiffert,
Fabrizio Schifano,
Michael Specka,
Udo Bonnet
and
Stefan Bender
![]()
Restricted
2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol) : A preliminary review. (2012)
John Corkery,
Fabrizio Schifano,
A. Hamid Ghodse,
S. Elliott
and
Ornella Corazza
![]()
The potential utility of some legal highs in CNS disorders. (2016)
Colin Davidson
and
Fabrizio Schifano
![]()
Identifying emerging trends in recreational drug use : outcomes from the Psychonaut Web Mapping Project. (2012)
Paolo Deluca,
Zoe Davey,
Ornella Corazza,
Manuela Pasinetti,
C. Pezzolesi,
Fabrizio Schifano,
Lucia Di Furia,
Magi Farre,
Marta Torrens,
Liv Flesland,
Arvid Skutle,
E. Iversen,
Miia Mannonen,
A. Majava,
Teuvo Peltoniemi,
Norbert Scherbaum,
Holger Siemann
and
Peer van der Kreeft
![]()
Suicide verdicts as opposed to accidental deaths in substance-related fatalities (UK, 2001–2007). (2011)
A.E. Vento,
M. Pompili,
Fabrizio Schifano,
John Corkery,
M. Innamorati,
P. Girardi
and
H. Ghodse
![]()